Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07641335 · ClinicalTrials.gov registry record · NA
Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players
A NA study, sponsored by St. Louis University.
- Not yet
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT07641335: Clinical Trial NA study, sponsored by St. Louis University.
NCT07641335 is a NA study that has not yet begun recruiting, run by St. Louis University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07641335, a NA study, has not yet begun recruiting, sponsored by St. Louis University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will examine whether caffeine improves cognitive and competitive performance in professional chess players during tournament-style games. In a randomized double-blind crossover design, participants will complete two experimental sessions in which they consume either caffeinated coffee or decaffeinated coffee before playing a standardized chess match. Cognitive performance will be assessed using attention and reaction-time tests, including the Stroop Test, Trail Making Test, and Puzzle Rush task. Chess performance outcomes such as move accuracy, time management, and error rates will also be evaluated. The study aims to determine whether moderate caffeine intake enhances focus, alertness, and decision-making during prolonged competitive chess play.
Primary Outcome
Chess performance accuracy will be assessed using engine-based analysis of tournament-style chess games. The primary reported metric will be average centipawn loss per move, with lower values indicating better chess performance accuracy.
Interventions
- DIETARY_SUPPLEMENT Caffeinated Coffee
- DIETARY_SUPPLEMENT Decaffeinated Coffee Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2027-08 |
| Phase | NA |
What is known before NCT07641335 opens enrollment
NCT07641335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Caffeinated Coffee is the first listed.
NCT07641335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07641335 about?
NCT07641335 is a clinical study titled "Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players". This study will examine whether caffeine improves cognitive and competitive performance in professional chess players during tournament-style games. In a randomized double-blind crossover design, participants will complete two experimental sessions in which they consume either caffeinated coffee or ...
What is the current status of trial NCT07641335?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2026-06-15. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07641335?
The interventions under investigation include: Caffeinated Coffee (DIETARY_SUPPLEMENT), Decaffeinated Coffee Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07641335?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07641335's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI